Alpha-9 Oncology

Biotech · Private

Selective radiopharmaceuticals for cancer treatment

a9oncology.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
4
1 granted · 3 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3332SIEYAX, INC——
3333Repare Therapeutics——
3334HOUSEY PHARMACEUTICAL RESEARCH LAB——
3335Alpha-9 Oncology——
3336ABBRATECH INC.——
3337PURE BIOSCIENCE, INC.—$29M
3338Timberlyne Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 4
  • Gastrin-releasing Peptide Receptor (grpr)-targeted Compounds And Uses Thereofapplication
  • Stable Radiopharmaceutical Compositions And Uses Thereofgranted
  • CXCR4-TARGETING Compounds, And Methods Of Making And Using The Sameapplication
  • Radiolabeled Compounds Targeting The Prostate-specific Membrane Antigenapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.